Compare SKY & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | TGTX |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.0B |
| IPO Year | N/A | 1995 |
| Metric | SKY | TGTX |
|---|---|---|
| Price | $90.99 | $31.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $101.00 | $51.60 |
| AVG Volume (30 Days) | 599.0K | ★ 2.4M |
| Earning Date | 02-03-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.48 | N/A |
| EPS | ★ 3.84 | 2.78 |
| Revenue | ★ $2,624,539,000.00 | $531,898,000.00 |
| Revenue This Year | $7.67 | $87.88 |
| Revenue Next Year | $4.67 | $47.78 |
| P/E Ratio | $23.89 | ★ $11.24 |
| Revenue Growth | 12.14 | ★ 100.88 |
| 52 Week Low | $59.44 | $25.28 |
| 52 Week High | $110.00 | $46.48 |
| Indicator | SKY | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 54.49 |
| Support Level | $92.36 | $29.80 |
| Resistance Level | $97.30 | $32.55 |
| Average True Range (ATR) | 3.29 | 1.63 |
| MACD | -0.41 | 0.30 |
| Stochastic Oscillator | 44.63 | 67.80 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.